Company Analysis Dechra Pharmaceuticals PLC
1. Summary
Advantages
- The stock's return over the last year (0%) is higher than the sector average (-17.15%).
Disadvantages
- Price (98 $) is higher than fair price (5.98 $)
- Dividends (0%) are below the sector average (0%).
- Current debt level 31.32% has increased over 5 years from 29.38%.
- The company's current efficiency (ROE=-3.69%) is lower than the sector average (ROE=0%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Dechra Pharmaceuticals PLC | Index | ||
|---|---|---|---|
| 7 days | 0% | 0.1% | 1.1% |
| 90 days | 0% | -0.4% | 9.1% |
| 1 year | 0% | -17.2% | 12.4% |
DPHAY vs Sector: Dechra Pharmaceuticals PLC has outperformed the "" sector by 17.15% over the past year.
DPHAY vs Market: Dechra Pharmaceuticals PLC has significantly underperformed the market by -12.35% over the past year.
Stable price: DPHAY is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: DPHAY with weekly volatility of 0% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (98 $) is higher than the fair price (5.98 $).
Price is higher than fair: The current price (98 $) is 93.9% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (53.05) is higher than that of the sector as a whole (0).
P/E vs Market: The company's P/E (53.05) is lower than that of the market as a whole (59.99).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (5.55) is higher than that of the sector as a whole (0).
P/BV vs Market: The company's P/BV (5.55) is higher than that of the market as a whole (3.41).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (5.51) is higher than that of the sector as a whole (0).
P/S vs Market: The company's P/S indicator (5.51) is higher than that of the market as a whole (3.65).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (47.14) is higher than that of the sector as a whole (0).
EV/Ebitda vs Market: The company's EV/Ebitda (47.14) is higher than that of the market as a whole (40.09).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -36.46% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-36.46%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0%).
5.4. ROE
ROE vs Sector: The company's ROE (-3.69%) is lower than that of the sector as a whole (0%).
ROE vs Market: The company's ROE (-3.69%) is lower than that of the market as a whole (41.13%).
5.5. ROA
ROA vs Sector: The company's ROA (-1.78%) is lower than that of the sector as a whole (0%).
ROA vs Market: The company's ROA (-1.78%) is lower than that of the market as a whole (29.31%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (11.01%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0% has been steadily paid over the past 7 years, DSI=0.79.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 2 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (76.98%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
